These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36172377)

  • 21. Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review.
    Margiotta DPE; Basta F; Batani V; Afeltra A
    BMC Nephrol; 2018 Mar; 19(1):54. PubMed ID: 29514612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 10 Years of belimumab experience: What have we learnt?
    Levy RA; Gonzalez-Rivera T; Khamashta M; Fox NL; Jones-Leone A; Rubin B; Burriss SW; Gairy K; Maurik AV; Roth DA
    Lupus; 2021 Oct; 30(11):1705-1721. PubMed ID: 34238087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
    Rovin BH; Furie R; Teng YKO; Contreras G; Malvar A; Yu X; Ji B; Green Y; Gonzalez-Rivera T; Bass D; Gilbride J; Tang CH; Roth DA
    Kidney Int; 2022 Feb; 101(2):403-413. PubMed ID: 34560137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
    Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes in lupus nephritis patients treated with belimumab in real-life setting: a retrospective comparative study in China.
    Lin Z; Jiang B; Wang W; Chen C; Wang Y; Wan J; Xu Y
    PeerJ; 2024; 12():e18028. PubMed ID: 39308826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
    van Schaik M; Arends EJ; Soonawala D; van Ommen E; de Leeuw K; Limper M; van Paassen P; Huizinga TWJ; Toes REM; van Kooten C; Rotmans JI; Rabelink TJ; Teng YKO
    Trials; 2022 Nov; 23(1):939. PubMed ID: 36371234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of belimumab in three cases of refractory lupus nephritis.
    Malaweera A; Dayan S; Pellicano R; Hoi A; Kitching AR; Kent JR
    Intern Med J; 2023 Oct; 53(10):1901-1906. PubMed ID: 37859540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Telitacicept in a systemic lupus erythematosus patient with suboptimal response to Belimumab: A case report.
    Huang L; Qian G; Zhang H; Li Q; Chen L; Tang X; Zhao H
    Lupus; 2024 Feb; 33(2):172-175. PubMed ID: 38081170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to belimumab among patients with refractory lupus nephritis: a real-world observational retrospective multicenter study.
    Zhang S; Qiu Q; Zeng S; Li H; Xu L; Jie L; Hu X; Xiao Y; Chen D; Zhan Z; Liang L; Yu Q; Xu H
    Clin Rheumatol; 2024 Jan; 43(1):199-208. PubMed ID: 37982925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful management of belimumab after obinutuzumab in a patient with systemic lupus erythematosus: a case report with an 18-month follow-up.
    Pu X; Ye Q; Zhu L; Yan T
    Front Immunol; 2024; 15():1459241. PubMed ID: 39421753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A "post-hoc" analysis of participants in the BLISS-LN and open label extension study belonging to a single center.
    Malvar A; Alberton V; Recalde C; Heguilen R
    Lupus; 2023 Oct; 32(12):1394-1401. PubMed ID: 37754750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.
    Furer V; Zisman D; Pokroy-Shapira E; Molad Y; Elkayam O; Paran D
    Scand J Rheumatol; 2016; 45(2):103-6. PubMed ID: 26515057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
    Furie R; Rovin BH; Houssiau F; Malvar A; Teng YKO; Contreras G; Amoura Z; Yu X; Mok CC; Santiago MB; Saxena A; Green Y; Ji B; Kleoudis C; Burriss SW; Barnett C; Roth DA
    N Engl J Med; 2020 Sep; 383(12):1117-1128. PubMed ID: 32937045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of belimumab therapy for patients with lupus nephritis: A meta-analysis and a propensity score-matched case-control study.
    Zhang K; Qi T; Guo D; Liu Y
    Immun Inflamm Dis; 2023 Jul; 11(7):e954. PubMed ID: 37506137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.
    Sciascia S; Radin M; Yazdany J; Levy RA; Roccatello D; Dall'Era M; Cuadrado MJ
    Autoimmun Rev; 2017 Mar; 16(3):287-293. PubMed ID: 28147262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
    Urowitz MB; Aranow C; Asukai Y; Bass DL; Bruce IN; Chauhan D; Dall'Era M; Furie R; Fox NL; Gilbride JA; Hammer A; Ginzler EM; Gonzalez-Rivera T; Levy RA; Merrill JT; Quasny H; Roth DA; Stohl W; van Vollenhoven R; Wallace DJ; Petri M
    Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1822-1828. PubMed ID: 35439360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis.
    Zhao L; Wang W; Wu L; Wu T; Tu J; Wu X; Sun F; Ding H; Shen N; Wu H; Zhu J; Sun L; Ye S
    Lupus Sci Med; 2024 May; 11(1):. PubMed ID: 38806217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
    J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.